Kiora Pharmaceuticals (KPRX)
(Real Time Quote from BATS)
$4.18 USD
-0.05 (-1.18%)
Updated Jul 15, 2024 11:48 AM ET
2-Buy of 5 2
A Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KPRX 4.18 -0.05(-1.18%)
Will KPRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KPRX
Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now?
Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update
KPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KPRX
Kiora Pharmaceuticals Inc trading halted, news pending
12 Health Care Stocks Moving In Thursday's After-Market Session
Buy Rating for Kiora Pharmaceuticals Bolstered by Strong Financials and Promising Clinical Trial Data
Buy Rating on Kiora Pharmaceuticals Amid Strong Financials and Promising Clinical Trials
KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q1 2024